A study to investigate the safety, tolerability, and pharmacokinetics (PK) of oral AZD6793 in healthy and Chronic Obstructive Pulmonary Disease participants, to assess the relative oral bioavailability between two formulations, and the food effect on the PK of AZD6793 compared to fasting state.

Study identifier:D7860C00001

ClinicalTrials.gov identifier:NCT05662033

EudraCT identifier:2022-002951-21

CTIS identifier:N/A

Recruiting

Official Title

A Blinded, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of an Oral Suspension of AZD6793 Following Single and Multiple Ascending Doses in Healthy Subjects, an Open-label Study to Assess the Relative Bioavailability and Food Effect of a Tablet Formulation of AZD6793 in Healthy Subjects and a Blinded, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of a Tablet Formulation of AZD6793 in Patients With Chronic Obstructive Pulmonary Disease

Medical condition

Inflammatory diseases

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD6793, Placebo

Sex

All

Estimated Enrollment

93

Study type

Interventional

Age

18 Years - 80 Years

Date

Study Start Date: 05 Dec 2022
Estimated Primary Completion Date: 08 Oct 2024
Estimated Study Completion Date: 08 Oct 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria